Previous work by us and other groups have shown that losartan can ameliorate the manifestation of muscle disease in mouse models of DMD, MDC1A, Marfan syndrome and sarcopenia, likely by attenuating the pro-fibrotic action of TGF-β signalling [10,13,16,30,31]. This evidence concerns the gene TGFB1 and Marfan syndrome.